Für weitere Publikationen besuchen Sie bitte Pubmed


Schicho A, Hellerbrand C, Krüger K, Beyer LP, Wohlgemuth W, Niessen C, Hohenstein E, Stroszczynski C, Pereira PL, Wiggermann P.
Impact of Different Embolic Agents for Transarterial Chemoembolization (TACE) Procedures on Systemic Vascular Endothelial Growth Factor (VEGF) Levels.
J Clin Transl Hepatol. 2016 Dec 284(4):288-292. doi: 10.14218/JCTH.2016.00058.

Sommer J, Mahli A, Freese K, Schiergens TS, Kuecuekoktay FS, Teufel A, Thasler WE, Müller M, Bosserhoff AK, Hellerbrand C.
Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice.
Oncotarget. 2016 Dec 30. doi: 10.18632/oncotarget.14371. [Epub ahead of print]

Mahli A, Hellerbrand C.
Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease.
Dig Dis. 201634 Suppl 1:32-9. doi: 10.1159/000447279. Review.

Teufel A, Itzel T, Erhart W, Brosch M, Wang XY, Kim YO, von Schönfels W, Herrmann A, Brückner S, Stickel F, Dufour JF, Chavakis T, Hellerbrand C, Spang R, Maass T, Becker T, Schreiber S, Schafmayer C, Schuppan D, Hampe J.
Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients.
Gastroenterology. 2016 Sep151(3):513-525.e0. doi: 10.1053/j.gastro.2016.05.051.

Hellerbrand C, Massoumi R.
Cylindromatosis–A Protective Molecule against Liver Diseases.
Med Res Rev. 2016 Mar36(2):342-59. doi: 10.1002/med.21381. Review.

Roeb E, Steffen HM, Bantel H, Baumann U, Canbay A, Demir M, Drebber U, Geier A, Hampe J, Hellerbrand C, Pathil-Warth A, Schattenberg JM, Schramm C, Seitz HK, Stefan N, Tacke F, Tannapfel A, Lynen Jansen P, Bojunga J.
[S2k Guideline non-alcoholic fatty liver disease].
Z Gastroenterol. 2015 Jul;53(7):668-723.

Scheller T, Hellerbrand C, Moser C, Schmidt K, Kroemer A, Brunner SM, Schlitt HJ, Geissler EK, Lang SA.
mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma.
Br J Cancer. 2015 Mar 3;112(5):841-50.

Schmidt K, Moser C, Hellerbrand C, Zieker D, Wagner C, Redekopf J, Schlitt HJ, Geissler EK, Lang SA.
Targeting Fibroblast Growth Factor Receptor (FGFR) with BGJ398 in a Gastric Cancer Model.
Anticancer Res. 2015 Dec35(12):6655-65.

Siegert I, Schödel J, Nairz M, Schatz V, Dettmer K, Dick C, Kalucka J, Franke K, Ehrenschwender M, Schley G, Beneke A, Sutter J, Moll M, Hellerbrand C, Wielockx B, Katschinski DM, Lang R, Galy B, Hentze MW, Koivunen P, Oefner PJ, Bogdan C, et al.
Ferritin-Mediated Iron Sequestration Stabilizes Hypoxia-Inducible Factor-1α upon LPS Activation in the Presence of Ample Oxygen.
Cell Rep. 2015 Dec 1513(10):2048-55. doi: 10.1016/j.celrep.2015.11.005.

Mahli A, Thasler WE, Patsenker E, Müller S, Stickel F, Müller M, Seitz HK, Cederbaum AI, Hellerbrand C.
Identification of cytochrome CYP2E1 as critical mediator of synergistic effects of alcohol and cellular lipid accumulation in hepatocytes in vitro.
Oncotarget. 2015 Dec 86(39):41464-78. doi: 10.18632/oncotarget.6203.

Buch S, Stickel F, Trépo E, Way M, Herrmann A, Nischalke HD, Brosch M, Rosendahl J, Berg T, Ridinger M, Rietschel M, McQuillin A, Frank J, Kiefer F, Schreiber S, Lieb W, Soyka M, Semmo N, Aigner E, Datz C, Schmelz R, Brückner S, et al.
A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis.
Nat Genet. 2015 Dec47(12):1443-8. doi: 10.1038/ng.3417.

Koch A, Lang SA, Wild PJ, Gantner S, Mahli A, Spanier G, Berneburg M, Müller M, Bosserhoff AK, Hellerbrand C.
Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells.
Oncotarget. 2015 Oct 206(32):32748-60. doi: 10.18632/oncotarget.4977.

Ruedel A, Dietrich P, Schubert T, Hofmeister S, Hellerbrand C, Bosserhoff AK.
Expression and function of microRNA-188-5p in activated rheumatoid arthritis synovial fibroblasts.
Int J Clin Exp Pathol. 2015 Jun 18(6):6607-16. Retraction in: Int J Clin Exp Pathol. 20158(11):15497.

Ruedel A, Dietrich P, Schubert T, Hofmeister S, Hellerbrand C, Bosserhoff AK.
Expression and function of microRNA-188-5p in activated rheumatoid arthritis synovial fibroblasts.
Int J Clin Exp Pathol. 2015 May 18(5):4953-62.

Seitz HK, Mueller S, Hellerbrand C, Liangpunsakul S.
Effect of chronic alcohol consumption on the development and progression of non-alcoholic fatty liver disease (NAFLD).
Hepatobiliary Surg Nutr. 2015 Jun4(3):147-51. doi: 10.3978/j.issn.2304-3881.2014.12.01. Review.

Roy S, Benz F, Vargas Cardenas D, Vucur M, Gautheron J, Schneider A, Hellerbrand C, Pottier N, Alder J, Tacke F, Trautwein C, Roderburg C, Luedde T.
miR-30c and miR-193 are a part of the TGF-β-dependent regulatory network controlling extracellular matrix genes in liver fibrosis.
J Dig Dis. 2015 Sep16(9):513-24. doi: 10.1111/1751-2980.12266.

Engelmann JC, Amann T, Ott-Rötzer B, Nützel M, Reinders Y, Reinders J, Thasler WE, Kristl T, Teufel A, Huber CG, Oefner PJ, Spang R, Hellerbrand C.
Causal Modeling of Cancer-Stromal Communication Identifies PAPPA as a Novel Stroma-Secreted Factor Activating NFκB Signaling in Hepatocellular Carcinoma.
PLoS Comput Biol. 2015 May 2811(5):e1004293. doi: 10.1371/journal.pcbi.1004293.

Weiskirchen R, Mahli A, Weiskirchen S, Hellerbrand C.
The hop constituent xanthohumol exhibits hepatoprotective effects and inhibits the activation of hepatic stellate cells at different levels.
Front Physiol. 2015 May 66:140. doi: 10.3389/fphys.2015.00140. Review.

Herrnberger L, Hennig R, Kremer W, Hellerbrand C, Goepferich A, Kalbitzer HR, Tamm ER.
Formation of fenestrae in murine liver sinusoids depends on plasmalemma vesicle-associated protein and is required for lipoprotein passage.
PLoS One. 2014 Dec 269(12):e115005. doi: 10.1371/journal.pone.0115005.

Padrissa-Altés S, Bachofner M, Bogorad RL, Pohlmeier L, Rossolini T, Böhm F, Liebisch G, Hellerbrand C, Koteliansky V, Speicher T, Werner S.
Control of hepatocyte proliferation and survival by Fgf receptors is essential for liver regeneration in mice.
Gut. 2015 Sep64(9):1444-53.

Bauer R, Valletta D, Bauer K, Thasler WE, Hartmann A, Müller M, Reichert TE, Hellerbrand C.
Downregulation of P-cadherin expression in hepatocellular carcinoma induces tumorigenicity.
Int J Clin Exp Pathol. 2014 Aug 157(9):6125-32.

Dietrich P, Hellerbrand C.
Non-alcoholic fatty liver disease, obesity and the metabolic syndrome.
Best Pract Res Clin Gastroenterol. 2014 Aug28(4):637-53. doi: 10.1016/j.bpg.2014.07.008. Review.

Krupar R, Robold K, Gaag D, Spanier G, Kreutz M, Renner K, Hellerbrand C, Hofstaedter F, Bosserhoff AK.
Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different.
Virchows Arch. 2014 Sep465(3):299-312. doi: 10.1007/s00428-014-1630-6.

Arndt S, Wacker E, Dorn C, Koch A, Saugspier M, Thasler WE, Hartmann A, Bosserhoff AK, Hellerbrand C.
Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease.
Gut. 2015 Jun64(6):973-81. doi: 10.1136/gutjnl-2014-306968.

Kanuri G, Wagnerberger S, Landmann M, Prigl E, Hellerbrand C, Bischoff SC, Bergheim I.
Effect of acute beer ingestion on the liver: studies in female mice.
Eur J Nutr. 2015 Apr54(3):465-74. doi: 10.1007/s00394-014-0730-z.

Pannem RR, Dorn C, Hellerbrand C, Massoumi R.
Cylindromatosis gene CYLD regulates hepatocyte growth factor expression in hepatic stellate cells through interaction with histone deacetylase 7.
Hepatology. 2014 Sep60(3):1066-81. doi: 10.1002/hep.27209.

Riener MO, Thiesler T, Hellerbrand C, Amann T, Cathomas G, Fritzsche FR, Dahl E, Bahra M, Weichert W, Terracciano L, Kristiansen G.
Loss of anterior gradient-2 expression is an independent prognostic factor in colorectal carcinomas.
Eur J Cancer. 2014 Jul50(10):1722-30. doi: 10.1016/j.ejca.2014.04.012.

Valletta D, Czech B, Spruss T, Ikenberg K, Wild P, Hartmann A, Weiss TS, Oefner PJ, Müller M, Bosserhoff AK, Hellerbrand C.
Regulation and function of the atypical cadherin FAT1 in hepatocellular carcinoma.
Carcinogenesis. 2014 Jun35(6):1407-15. doi: 10.1093/carcin/bgu054.

Dorn C, Engelmann JC, Saugspier M, Koch A, Hartmann A, Müller M, Spang R, Bosserhoff A, Hellerbrand C.
Increased expression of c-Jun in nonalcoholic fatty liver disease.
Lab Invest. 2014 Apr94(4):394-408. doi: 10.1038/labinvest.2014.3.

Köhler UA, Kurinna S, Schwitter D, Marti A, Schäfer M, Hellerbrand C, Speicher T, Werner S.
Activated Nrf2 impairs liver regeneration in mice by activation of genes involved in cell-cycle control and apoptosis.
Hepatology. 2014 Aug60(2):670-8. doi: 10.1002/hep.26964.

Hellerbrand C.
Molecular targets for antifibrotic therapy in liver disease: using magic bullets for crossfire rather than a one-sided shotgun attack.
Gut. 2014 Jul63(7):1039-41. doi: 10.1136/gutjnl-2013-305908. No abstract available.

Pannem RR, Dorn C, Ahlqvist K, Bosserhoff AK, Hellerbrand C, Massoumi R.
CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma.
Carcinogenesis. 2014 Feb35(2):461-8. doi: 10.1093/carcin/bgt335.